Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women

被引:151
作者
Yang, Wei-Tse [1 ]
Dryden, Mark [1 ]
Broglio, Kristine [2 ]
Gilcrease, Michael [3 ]
Dawood, Shaheenah [4 ]
Dempsey, Peter J. [1 ]
Valero, Vicente [4 ]
Hortobagyi, Gabriel [4 ]
Atchley, Deann [4 ]
Arun, Banu [4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77230 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77230 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77230 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77230 USA
关键词
mammography; triple receptor-negative; breast cancer; breast density; microcalcifications;
D O I
10.1007/s10549-007-9810-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The mammographic features of triple receptor-negative [TRN] breast cancers, a distinct cancer subtype with a poor prognosis have not been reported to our knowledge. The aim of this study was to compare the mammographic breast density, visibility, and tumor features of different breast cancer immunophenotypes. Patients and methods We identified all premenopausal women aged 45 years or less who had been diagnosed with primary breast cancer between January 1999 and November 2005 at a single institution and who had undergone mammography at initial diagnosis. Patient characteristics including clinical, histologic, and mammographic features of breast cancers were tabulated by immunophenotype and compared with the chi-square test or the Kruskal-Wallis test. The P values less than 0.05 were considered statistically significant. Results We identified 198 premenopausal women who had been diagnosed with breast cancer. Thirty-eight (19%) women had TRN cancer, 67 (34%) had HER2+ cancer, and 93 (47%) had ER+ cancer. Mammographic density and cancer visibility were similar between all immunophenotypes of cancers. TRN cancers were more frequently associated with a mass (33/33 [100%]) than were HER2+ (35/64 [55%]) and ER+ cancers (42/87 [48%]) (P < 0.0001), and were less frequently associated with calcifications (5/33 [15%]) than were HER2+ (43/64 [67%]) and ER+ (53/87 [61%]) cancers (P < 0.0001). Associated ductal carcinoma in situ was reported in 18% (7/38), 57% (38/67), and 48% (52/93) of TRN, HER2+, and ER+ patients, respectively (P = 0.0003). Conclusion The mammographic features of TRN breast cancer suggest more rapid carcinogenesis leading directly to invasive cancer, that may require adjunct imaging tools for early diagnosis.
引用
收藏
页码:405 / 410
页数:6
相关论文
共 47 条
[21]   Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition [J].
Kriege, M ;
Brekelmans, CTM ;
Boetes, C ;
Besnard, PE ;
Zonderland, HM ;
Obdeijn, IM ;
Manoliu, RA ;
Kok, T ;
Peterse, H ;
Tilanus-Linthorst, MMA ;
Muller, SH ;
Meijer, S ;
Oosterwijk, JC ;
Beex, LVAM ;
Tollenaar, RAEM ;
de Koning, HJ ;
Rutgers, EJT ;
Klijn, JGM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :427-437
[22]   Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer [J].
Kuhl, CK ;
Schrading, S ;
Leutner, CC ;
Morakkabati-Spitz, N ;
Wardelmann, E ;
Fimmers, R ;
Kuhn, W ;
Schild, HH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8469-8476
[23]   Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results [J].
Kuhl, CK ;
Schmutzler, RK ;
Leutner, CC ;
Kempe, A ;
Wardelmann, E ;
Hocke, A ;
Maringa, M ;
Pfeifer, U ;
Krebs, D ;
Schild, HH .
RADIOLOGY, 2000, 215 (01) :267-279
[24]   Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations [J].
Lakhani, SR ;
Jacquemier, J ;
Sloane, JP ;
Gusterson, BA ;
Anderson, TJ ;
van de Vijver, MJ ;
Farid, LM ;
Venter, D ;
Antoniou, A ;
Storfer-Isser, A ;
Smyth, E ;
Steel, CM ;
Haites, N ;
Scott, RJ ;
Goldgar, D ;
Neuhausen, S ;
Daly, PA ;
Ormiston, W ;
McManus, R ;
Scherneck, S ;
Ponder, BAJ ;
Ford, D ;
Peto, J ;
Stoppa-Lyonnet, D ;
Bignon, YJ ;
Struewing, JP ;
Spurr, NK ;
Bishop, DT ;
Klijn, JGM ;
Devilee, P ;
Cornelisse, CJ ;
Lasset, C ;
Lenoir, G ;
Barkardottir, RB ;
Egilsson, V ;
Hamann, U ;
Chang-Claude, J ;
Sobol, H ;
Weber, B ;
Stratton, MR ;
Easton, DF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (15) :1138-1145
[25]  
Lakhani SR, 1997, LANCET, V349, P1505
[26]  
Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO
[27]  
2-W
[28]  
MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23
[29]  
MOORE OS, 1949, CANCER, V2, P635, DOI 10.1002/1097-0142(194907)2:4<635::AID-CNCR2820020411>3.0.CO
[30]  
2-Q